AIM: To explore the anti- @entity5 immunity against CT26 @entity694 of the microencapsulated cells modified with @entity19 interleukine-12 (mIL-12) gene. METHODS: @entity19 fibroblasts (NIH3T3) were stably transfected to express mIL-12 using expression plasmids carrying mIL-12 gene ( @entity10357 and @entity12782 ), and NIH3T3-mIL-12 cells were encapsulated in alginate microcapsules for long-term delivery of mIL-12. mIL-12 released from the microencapsulated NIH3T3-mIL-12 cells was confirmed using ELISA assay. Transplantation of the microencapsulated NIH3T3-mIL-12 cells was performed in the @entity5 -bearing @entity19 with CT26 cells. The anti- @entity5 responses and the anti- @entity5 activities of the microencapsulated NIH3T3-mIL-12 cells were evaluated. RESULTS: Microencapsulated NIH3T3-mIL-12 cells could release mIL-12 continuously and stably for a long time. After the microencapsulated NIH3T3-mIL-12 cells were transplanted subcutaneously into the @entity5 -bearing @entity19 for 21 d, the serum concentrations of mIL-12, @entity2047 and @entity60 , the @entity137 of the CTL from the splenocytes and the NK activity in the treatment group were significantly higher than those in the controls. Moreover, mIL-12 released from the microencapsulated NIH3T3-mIL-12 cells resulted in a significant inhibition of @entity5 proliferation and a prolonged survival of @entity5 -bearing @entity19 . CONCLUSION: The microencapsulated NIH3T3-mIL-12 cells have a significant therapeutic effect on the experimental @entity694 by activating anti- @entity5 immune responses in vivo. Microencapsulated and genetically engineered cells may be an extremely versatile tool for @entity5 gene therapy.

Continuous release of interleukin 12 from microencapsulated engineered cells for XXXX therapy.

@entity137 :: ('MESH:D064420', 'Disease') :: ['cytotoxicity'] @entity12782 :: ('16160(Tax:10090)', 'Gene') :: ['p40'] @entity2047 :: ('16183(Tax:10090)', 'Gene') :: ['mIL-2'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity19 :: ('10090', 'Species') :: ['mice', 'Mouse', 'murine'] @entity60 :: ('15978(Tax:10090)', 'Gene') :: ['mIFN-gamma'] @entity694 :: ('MESH:D003110', 'Disease') :: ['colon tumor'] @entity10357 :: ('16159(Tax:10090)', 'Gene') :: ['p35']
@entity694 :: (MESH:D003110,Disease) :: ['colon cancer']
